BACKGROUND & AIMS: The aim of this study was to describe 3-month and 1-year outcomes of children with Crohn's disease (CD) treated with corticosteroids within 30 days of diagnosis, with particular emphasis on the influence of infliximab on these outcomes. We also aimed to determine whether there are clinical or laboratory characteristics associated with corticosteroid therapy outcomes. METHODS: Data from 109 children were drawn from a multicenter observational registry that was started in 2002. Clinical characteristics and data on corticosteroid and other therapies were recorded prospectively. Corticosteroid therapy outcomes at 3 months were defined as complete acute response, partial response, or corticosteroid resistance. At 1 year, corticosteroid responsiveness, dependence, and surgical rates were determined. Infliximab's influence on short- and long-term outcomes also was investigated. RESULTS: At 3 months, 65 of 109 (60%) patients had a complete acute response to corticosteroids, 26 (24%) had a partial response, and 18 (17%) were corticosteroid resistant. At 1 year, 61% were corticosteroid responsive, 31% were corticosteroid dependent, and 8% required surgery. Irrespective of the duration of corticosteroid treatment, 16 of 24 of corticosteroid-dependent/resistant patients rapidly discontinued corticosteroids after starting infliximab. No clinical or laboratory characteristics at diagnosis predicted short-term outcome. Growth impairment at diagnosis increased risk for corticosteroid dependence or surgery at 1 year. CONCLUSIONS: At 3 months, 84% of children had a complete or partial response to corticosteroids. However, despite concomitant immunomodulators, at 1 year 31% were corticosteroid dependent and 8% required surgery. Infliximab improves outcomes of corticosteroid-dependent/resistant patients because the duration of corticosteroid use can be controlled by initiating treatment with infliximab.
BACKGROUND & AIMS: The aim of this study was to describe 3-month and 1-year outcomes of children with Crohn's disease (CD) treated with corticosteroids within 30 days of diagnosis, with particular emphasis on the influence of infliximab on these outcomes. We also aimed to determine whether there are clinical or laboratory characteristics associated with corticosteroid therapy outcomes. METHODS: Data from 109 children were drawn from a multicenter observational registry that was started in 2002. Clinical characteristics and data on corticosteroid and other therapies were recorded prospectively. Corticosteroid therapy outcomes at 3 months were defined as complete acute response, partial response, or corticosteroid resistance. At 1 year, corticosteroid responsiveness, dependence, and surgical rates were determined. Infliximab's influence on short- and long-term outcomes also was investigated. RESULTS: At 3 months, 65 of 109 (60%) patients had a complete acute response to corticosteroids, 26 (24%) had a partial response, and 18 (17%) were corticosteroid resistant. At 1 year, 61% were corticosteroid responsive, 31% were corticosteroid dependent, and 8% required surgery. Irrespective of the duration of corticosteroid treatment, 16 of 24 of corticosteroid-dependent/resistant patients rapidly discontinued corticosteroids after starting infliximab. No clinical or laboratory characteristics at diagnosis predicted short-term outcome. Growth impairment at diagnosis increased risk for corticosteroid dependence or surgery at 1 year. CONCLUSIONS: At 3 months, 84% of children had a complete or partial response to corticosteroids. However, despite concomitant immunomodulators, at 1 year 31% were corticosteroid dependent and 8% required surgery. Infliximab improves outcomes of corticosteroid-dependent/resistant patients because the duration of corticosteroid use can be controlled by initiating treatment with infliximab.
Authors: Jong Seung Lee; Jee Hyun Lee; Ji Hyuk Lee; Hye Jin Lee; Mi Jin Kim; Hae Jeong Lee; Yon Ho Choe Journal: World J Gastroenterol Date: 2010-04-14 Impact factor: 5.742
Authors: Christine Mrakotsky; Peter W Forbes; Jane Holmes Bernstein; Richard J Grand; Athos Bousvaros; Eva Szigethy; Deborah P Waber Journal: J Int Neuropsychol Soc Date: 2012-11-19 Impact factor: 2.892
Authors: Tonya Adamiak; Dorota Walkiewicz-Jedrzejczak; Daryl Fish; Christopher Brown; Jeanne Tung; Khalid Khan; William Faubion; Roger Park; Janice Heikenen; Michael Yaffee; Maria T Rivera-Bennett; Marcy Wiedkamp; Michael Stephens; Richard Noel; Melodee Nugent; Justin Nebel; Pippa Simpson; Michael D Kappelman; Subra Kugathasan Journal: Inflamm Bowel Dis Date: 2013-05 Impact factor: 5.325
Authors: B Weiss; O Lebowitz; H H Fidder; I Maza; A Levine; R Shaoul; S Reif; Y Bujanover; A Karban Journal: Dig Dis Sci Date: 2009-08-20 Impact factor: 3.199
Authors: Marla C Dubinsky; Subra Kugathasan; Ling Mei; Yoana Picornell; Justin Nebel; Iwona Wrobel; Antonio Quiros; Gary Silber; Ghassan Wahbeh; Lirona Katzir; Eric Vasiliauskas; Ron Bahar; Anthony Otley; David Mack; Jonathan Evans; Joel Rosh; Maria Oliva Hemker; Neal Leleiko; Wallace Crandall; Christine Langton; Carol Landers; Kent D Taylor; Stephan R Targan; Jerome I Rotter; James Markowitz; Jeffrey Hyams Journal: Clin Gastroenterol Hepatol Date: 2008-07-10 Impact factor: 11.382